[HTML][HTML] Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for≥ 156 weeks from 2 phase 3, randomized, controlled trials …
Background Randomized, controlled trials demonstrated efficacy and safety of apremilast for
moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective Assess long-term …
moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective Assess long-term …
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for≥ 156 weeks from 2 phase 3, randomized, controlled trials …
J Crowley, D Thaçi, P Joly, K Peris… - Journal of the …, 2017 - pubmed.ncbi.nlm.nih.gov
Background Randomized, controlled trials demonstrated efficacy and safety of apremilast for
moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective Assess long-term …
moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective Assess long-term …
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for≥ 156 weeks from 2 phase 3, randomized, controlled trials …
J Crowley, D Thaçi, P Joly, K Peris, K Papp… - Journal of The …, 2017 - udl.hal.science
Background: Randomized, controlled trials demonstrated efficacy and safety of apremilast
for moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective: Assess long-term …
for moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective: Assess long-term …
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for≥ 156 weeks from 2 phase 3, randomized, controlled trials …
J Crowley, D Thaçi, P Joly, K Peris… - JOURNAL OF THE …, 2017 - publicatt.unicatt.it
Background: Randomized, controlled trials demonstrated efficacy and safety of apremilast
for moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective: Assess long-term …
for moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective: Assess long-term …
[引用][C] Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for≥ 156 weeks from 2 phase 3, randomized, controlled trials …
J Crowley, D Thaçi, P Joly, K Peris, KA Papp… - Journal of the American …, 2017 - cir.nii.ac.jp
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis
for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2) | CiNii …
for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2) | CiNii …
[HTML][HTML] Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for≥ 156 weeks from 2 phase 3, randomized, controlled trials …
J Crowley, D Thaçi, P Joly, K Peris, KA Papp… - Journal of the American …, 2017 - jaad.org
Background Randomized, controlled trials demonstrated efficacy and safety of apremilast for
moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective Assess long-term …
moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective Assess long-term …
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for≥ 156 weeks from 2 phase 3, randomized, controlled trials …
J Crowley, D Thaçi, P Joly, K Peris… - Journal of the …, 2017 - research.uni-luebeck.de
Background Randomized, controlled trials demonstrated efficacy and safety of apremilast for
moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective Assess long-term …
moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective Assess long-term …
[PDF][PDF] Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for≥ 156 weeks from 2 phase 3, randomized, controlled trials …
J Crowley, D Thaçi, P Joly, K Peris, K Papp… - Journal of The …, 2017 - hal.science
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis
for 156 weeks from 2 phase 3 Page 1 HAL Id: hal-02467951 https://hal.science/hal-02467951 …
for 156 weeks from 2 phase 3 Page 1 HAL Id: hal-02467951 https://hal.science/hal-02467951 …
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for≥ 156 weeks from 2 phase 3, randomized, controlled trials …
J Crowley, D Thaçi, P Joly, K Peris… - Journal of The …, 2017 - univ-lyon1.hal.science
Background: Randomized, controlled trials demonstrated efficacy and safety of apremilast
for moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective: Assess long-term …
for moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective: Assess long-term …
[PDF][PDF] Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for $156 weeks from 2 phase 3, randomized, controlled trials …
J Crowley, D Thaçi, P Joly, K Peris, KA Papp… - 2017 - academia.edu
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis
for $156 weeks from 2 phase 3 Page 1 Long-term safety and tolerability of apremilast in patients …
for $156 weeks from 2 phase 3 Page 1 Long-term safety and tolerability of apremilast in patients …